Viking Therapeutics reported net income of -$183.73M for the quarter ended Sep 2026. This income statement covers 51 quarters of results from Mar 2014 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Mar2014 | Jun2014 | Sep2014 | Dec2014 | Mar2015 | Jun2015 | Sep2015 | Dec2015 | Mar2016 | Jun2016 | Sep2016 | Dec2016 | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating items | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization - Intangibles | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 9.85M | 12.56M | 13.54M | 11.96M | 16.18M | 11.01M | 13.92M | 18.38M | 20.50M | 24.10M | 23.77M | 22.79M | 30.99M | 41.39M | 60.15M | 89.95M | 153.46M | 150.15M | 115.75M | 166.80M | |||||||||||||||||||||||||||||||
| Selling, General & AdministrativeSG&A | 2.66M | 3.69M | 4.09M | 4.24M | 4.11M | 9.53M | 9.82M | 8.89M | 8.78M | 9.97M | 10.29M | 13.77M | 15.25M | 14.08M | 14.42M | 8.61M | 11.28M | 13.98M | 16.84M | 20.31M | |||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 12.51M | 16.25M | 17.63M | 16.20M | 20.28M | 20.54M | 23.74M | 27.27M | 29.29M | 34.07M | 34.05M | 36.56M | 46.24M | 55.47M | 74.57M | 98.56M | 164.74M | 164.13M | 132.60M | 187.11M | |||||||||||||||||||||||||||||||
| Operating IncomeOp. Inc | -12.51M | -16.25M | -17.63M | -16.20M | -20.28M | -20.54M | -23.74M | -27.27M | -29.29M | -34.07M | -34.05M | -36.56M | -46.24M | -55.47M | -74.57M | -98.56M | -164.74M | -164.13M | -132.60M | -187.11M | |||||||||||||||||||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.09M | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Gains (Losses) on Sale of Assets & InvestmentsGains on Sales | -0.38M | -0.89M | -0.03M | 0.11M | 0.77M | 0.50M | -1.13M | 0.00M | 0.11M | 0.00M | 0.56M | 0.00M | 0.01M | 0.04M | -1.25M | 0.03M | |||||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 7.77M | 4.01M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.15M | 0.14M | 0.20M | 0.42M | 0.72M | 1.01M | 4.52M | 4.73M | 4.68M | 6.72M | 11.80M | 11.62M | 10.82M | 9.84M | 9.01M | 7.77M | 7.08M | 5.80M | 4.58M | 3.93M | |||||||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.15M | 0.14M | 0.20M | 0.42M | 0.72M | 1.01M | 4.52M | 4.73M | 4.68M | 6.72M | 11.80M | 11.62M | 10.82M | 9.84M | 9.01M | 7.77M | 7.08M | 5.80M | 4.58M | 3.93M | |||||||||||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||||||||||||||||||
| EBIT | -12.51M | -16.25M | -17.63M | -16.20M | -20.28M | -20.54M | -23.74M | -27.27M | -29.29M | -34.07M | -34.05M | -36.56M | -46.24M | -55.47M | -74.57M | -98.56M | -164.74M | -164.13M | -132.60M | -187.11M | |||||||||||||||||||||||||||||||
| EBT | -12.51M | -16.25M | -17.63M | -16.20M | -20.28M | -20.54M | -23.74M | -27.27M | -29.29M | -34.07M | -34.05M | -36.56M | -46.24M | -55.47M | -74.57M | -90.79M | -164.74M | -164.13M | -132.60M | -183.19M | |||||||||||||||||||||||||||||||
| Income After Tax | -12.51M | -16.25M | -17.63M | -16.20M | -20.28M | -20.54M | -23.74M | -27.27M | -29.29M | -34.07M | -34.05M | -36.56M | -46.24M | -55.47M | -74.57M | -90.79M | -164.74M | -164.13M | -132.60M | -183.19M | |||||||||||||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -12.51M | -16.25M | -17.63M | -16.20M | -20.28M | -20.54M | -23.74M | -27.27M | -29.29M | -34.07M | -34.05M | -36.56M | -46.24M | -55.47M | -74.57M | -90.79M | -164.74M | -164.13M | -132.60M | -183.19M | |||||||||||||||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -12.74M | -16.97M | -17.67M | -15.89M | -18.90M | -19.05M | -19.65M | -22.40M | -24.09M | -28.57M | -22.92M | -21.04M | -37.84M | -45.06M | -65.51M | -90.25M | -157.66M | -159.56M | -128.32M | -183.73M | |||||||||||||||||||||||||||||||
| Income towards Parent CompanyParent Net Inc | -12.36M | -16.10M | -17.43M | -15.77M | -19.56M | -19.53M | -19.23M | -22.53M | -24.61M | -27.36M | -22.25M | -24.94M | -35.42M | -45.63M | -65.56M | -90.79M | -157.66M | -158.33M | -128.02M | -183.19M | |||||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -12.36M | -16.10M | -17.43M | -15.77M | -19.56M | -19.53M | -19.23M | -22.53M | -24.61M | -27.36M | -22.25M | -24.94M | -35.42M | -45.63M | -65.56M | -90.79M | -157.66M | -158.33M | -128.02M | -183.19M | |||||||||||||||||||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.16 | -0.21 | -0.23 | -0.21 | -0.25 | -0.25 | -0.19 | -0.23 | -0.26 | -0.26 | -0.20 | -0.22 | -0.32 | -0.41 | -0.58 | -0.81 | -1.40 | -1.37 | -1.10 | -1.55 | |||||||||||||||||||||||||||||||
| EPS (Diluted) | -0.16 | -0.21 | -0.23 | -0.21 | -0.25 | -0.25 | -0.19 | -0.23 | -0.26 | -0.26 | -0.20 | -0.22 | -0.32 | -0.41 | -0.58 | -0.81 | -1.40 | -1.37 | -1.10 | -1.55 | |||||||||||||||||||||||||||||||
| Shares Outstanding | 77.38M | 77.60M | 77.03M | 76.69M | 77.02M | 78.53M | 99.19M | 100.03M | 94.53M | 103.64M | 110.57M | 111.09M | 109.22M | 112.25M | 112.32M | 112.44M | 112.79M | 115.60M | 116.29M | 118.08M | |||||||||||||||||||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 77.20M | 77.41M | 76.84M | 76.51M | 76.83M | 78.35M | 99.01M | 99.85M | 94.35M | 103.46M | 110.39M | 110.91M | 109.04M | 112.07M | 112.13M | 112.32M | 112.67M | 115.57M | 116.26M | 118.05M | |||||||||||||||||||||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 78.25M | 77.37M | 76.69M | 76.69M | 78.26M | 79.32M | 100.03M | 100.03M | 100.11M | 110.23M | 110.80M | 111.43M | 111.57M | 112.29M | 112.33M | 112.45M | 114.79M | 115.89M | 116.65M | 127.52M | |||||||||||||||||||||||||||||||
| Interest ExpensesInt Expense | 0.09M |
Pull Viking Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=VKTX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "VKTX", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=VKTX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();